BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33708956)

  • 1. The effect of primary site, functional status and treatment modality on survival in gastroenteropancreatic neuroendocrine neoplasms with synchronous liver metastasis: a US population-based study.
    Pu N; Habib JR; Bejjani M; Yin H; Nagai M; Chen J; Kinny-Köster B; Chen Q; Zhang J; Yu J; Wu W; Lou W
    Ann Transl Med; 2021 Feb; 9(4):329. PubMed ID: 33708956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiologic trends and survival of early-onset gastroenteropancreatic neuroendocrine neoplasms.
    Yao H; Hu G; Jiang C; Fan M; Yuan L; Shi H; Lin R
    Front Endocrinol (Lausanne); 2023; 14():1241724. PubMed ID: 37701903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm.
    Wang Y; Chen Y; Li X; Hu W; Zhang Y; Chen L; Chen M; Chen J
    BMC Cancer; 2018 Jun; 18(1):691. PubMed ID: 29940892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Nomogram to Predict Individual Survival of Patients with Liver-Limited Metastases from Gastroenteropancreatic Neuroendocrine Neoplasms: A US Population-Based Cohort Analysis and Chinese Multicenter Cohort Validation Study.
    Xu G; Xiao Y; Hu H; Jin B; Wu X; Wan X; Zheng Y; Xu H; Lu X; Sang X; Ge P; Mao Y; Cai J; Zhao H; Du S
    Neuroendocrinology; 2022; 112(3):263-275. PubMed ID: 33902058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
    Shi H; Zhang Q; Han C; Zhen D; Lin R
    BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of surgical treatments in high-grade or advanced gastroenteropancreatic neuroendocrine neoplasms.
    Que QY; Zhang LC; Bao JQ; Ling SB; Xu X
    World J Gastrointest Surg; 2022 May; 14(5):397-408. PubMed ID: 35734618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study.
    Poleé IN; Hermans BCM; van der Zwan JM; Bouwense SAW; Dercksen MW; Eskens FALM; Havekes B; Hofland J; Kerkhofs TMA; Klümpen HJ; Latten-Jansen LM; Speel EM; Verburg FA; Walenkamp AME; Geurts SME; de Vos-Geelen J
    Eur J Cancer; 2022 Sep; 172():252-263. PubMed ID: 35803176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china.
    Fan JH; Zhang YQ; Shi SS; Chen YJ; Yuan XH; Jiang LM; Wang SM; Ma L; He YT; Feng CY; Sun XB; Liu Q; Deloso K; Chi Y; Qiao YL
    Oncotarget; 2017 Sep; 8(42):71699-71708. PubMed ID: 29069739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.
    Zheng M; Li Y; Li T; Zhang L; Zhou L
    Cancer Med; 2019 Sep; 8(11):5128-5136. PubMed ID: 31328428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study.
    Feola T; Puliani G; Sesti F; Modica R; Centello R; Minotta R; Cannavale G; Di Meglio S; Di Vito V; Lauretta R; Appetecchia M; Colao A; Lenzi A; Isidori AM; Faggiano A; Giannetta E
    J Endocrinol Invest; 2022 Apr; 45(4):849-857. PubMed ID: 35040099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
    Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
    Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms.
    Huang PY; Tsai KL; Liang CM; Tai WC; Rau KM; Wu KL; Huang CC; Chuah SK
    Kaohsiung J Med Sci; 2018 Nov; 34(11):650-656. PubMed ID: 30392572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid-derived suppressor cells in gastroenteropancreatic neuroendocrine neoplasms.
    Liu M; Zhang Y; Chen L; Lin Y; He Q; Zeng Y; Chen M; Chen J
    Endocrine; 2021 Jan; 71(1):242-252. PubMed ID: 33010002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms].
    Li Y; Wang YF; Tan BB; Er LM; Zhao Q; Fan LQ; Zhang ZD; Liu Y
    Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):426-431. PubMed ID: 32482035
    [No Abstract]   [Full Text] [Related]  

  • 16. Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China.
    Wang YH; Lin Y; Xue L; Wang JH; Chen MH; Chen J
    BMC Endocr Disord; 2012 Nov; 12():30. PubMed ID: 23194346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of World Health Organization 2010 Classification for Gastroenteropancreatic Neuroendocrine Neoplasms with the Prognosis of Ovarian Neuroendocrine Neoplasms: Kansai Clinical Oncology Group-Protocol Review Committee/Intergroup Study.
    Kai K; Nasu K; Nishida H; Daa T; Shikama A; Shiozaki T; Kurakazu M; Yano M; Imamura Y; Tokunaga H; Tasaki K; Iida Y; Yamada Y; Morisawa H; Nakagawa S; Fujimoto E; Tsuruta T; Matsumoto H; Arakawa A; Nonaka M; Takano H; Ushiwaka T; Mori T; Ito K; Motohashi T; Teramoto N; Yamada T
    Neuroendocrinology; 2021; 111(4):320-329. PubMed ID: 32097950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
    Masui T; Ito T; Komoto I; Uemoto S;
    BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update.
    Kole C; Charalampakis N; Vailas M; Tolia M; Sotiropoulou M; Tsakatikas S; Kouris NI; Tsoli M; Koumarianou A; Karamouzis MV; Schizas D
    Cancer Immunol Immunother; 2022 Apr; 71(4):761-768. PubMed ID: 34471940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Features and Long-Term Survival of Metastatic Hepatic Neuroendocrine Neoplasms Secondary to Gastroenteropancreatic Site: An Analysis by Applying the Grading Classification.
    Yang M; Zeng L; Hou SZ; Ke NW; Tian BL; Liu XB; Xiang B; Zhang Y
    J Oncol; 2020; 2020():6572398. PubMed ID: 33014053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.